Effects of Pabolizumab Combined with Gemcitabine and Cisplatin on the Expression Levels of T Cell Subsets and Serum PDCD5 and COL4A3 in Patients with Lung Cancer
Objective To investigate the effects of pabolizumab combined with gemcitabine and cisplatin(GP)on the expression levels of T cell subsets and serum programmed cell death protein 5(PDCD5)and type Ⅳ collagen α3(COL4A3)in patients with lung cancer.Methods A total of 116 patients with lung cancer admitted to the Second People's Hospital of Luohe from January 2020 to May 2022 were divided into control group and observation group according to treatment plan,with 58 cases in each group.The control group was treated with GP chemotherapy,and the observation group was treated with pabolizumab combined with GP chemotherapy.Clinical efficacy,CFS score,T cell subsets(CD3+,CD4+,CD8+,CD4+/CD8+),serum cytokines[carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199),PDCD5,COL4A3]levels,1 year survival rate were compared between the two groups.Results The disease control rate(DCR)of the observation group was higher than that of the control group(P＜0.05).After 3 courses of treatment,the CFS score of the observation group was lower than that of the control group(P＜0.05),the levels of CD3+,CD4+,CD4+/CD8+were higher than those of the control group,the level of CD8+was lower than that of the control group(P＜0.05),the levels of serum CA125,CA199,and COL4A3 were lower than those of the control group,and the level of PDCD5 was higher than that of the control group(P＜0.05).The 1 year survival rate of the observation group was higher than that of the control group(P＜0.05).Conclusion Pabolizumab combined with GP chemotherapy in the treatment of lung cancer patients can effectively reduce immune function injury,inhibit disease progression,alleviate cancer-related fatigue,enhance curative effect and prolong survival.
lung cancerpabolizumabgemcitabinecisplatinchemotherapyprogrammed cell death protein 5type Ⅳcollagen alpha3
万方数据
维普
